J Obes Metab Syndr 2021; 30(1): 1-3
Published online March 30, 2021 https://doi.org/10.7570/jomes21011
Copyright © Korean Society for the Study of Obesity.
1Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul;
2Asan Diabetes Center, Asan Medical Center, Seoul, Korea
Chang Hee Jung
Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Obesity is associated with various cardiometabolic diseases and increased mortality.1 However, a select group of obese individuals, the metabolically healthy obese (MHO), characterized by absence of metabolic disturbances, appear to be spared from the ominous complications of obesity.2,3 In South Korea, the prevalence of obesity has increased in all age groups over the last decade and reached 35.7% in 2018.1 According to a meta-analysis, the prevalence of MHO reported in previous studies was largely variable depending on the definition of MHO used, ranging from 13% to 86%.2 There are also regional and sex differences in the prevalence of MHO.2 Although the mechanism of preservation of metabolic health in the MHO group has been investigated in both human and animal studies, it remains unknown.3,4 The suggested mechanisms include subcutaneous fat distribution, adipose tissue expandability, sustained insulin sensitivity, preserved adipocyte function, chronic inflammation, and genetic associations.3-5 Environmental and behavioral factors, such as an individual’s physical activity level and self-rated health (SRH), also have been proposed.6
The prognosis of MHO in association with type 2 diabetes and cardiovascular disease (CVD) is controversial. Some studies have demonstrated that MHO individuals show a favorable prognosis and advocated that MHO be classified as a “benign condition.”5 However, some studies have opposed this concept and reported that MHO individuals have higher risk of type 2 diabetes, CVD, and mortality.7 Accumulated evidence regarding the increased risk of type 2 diabetes and CVD among MHO individuals compared to that in metabolically healthy normal weight (MHNW) individuals suggests that MHO is not a “benign condition.”3,7
In a previous study, the SRH of subjects with obesity and metabolic syndrome was worse than that reported by non-obese subjects.6 In addition, low SRH in MHO individuals was associated with progression to metabolically unhealthy obese (MUO) status.6 In another study, impaired glucose tolerance was associated with low SRH.8 In line with these results, a recent study by Hjelmgren et al.9 published in
Previous studies on the level of physical activity of MHO individuals have reported inconsistent results.10,11 A study by de Winter et al.11 reported no difference in the level of physical activity between MHO and MUO groups; however, de Rooij et al.10 concluded that the MHO group performed more physical activity than the MUO group. A study by Hjelmgren et al.9 provided evidence supporting the study by de Winter et al.11; the number of individuals performing leisure-time physical activity for >30 minutes at least 1–2 times a week was not significantly different between MHO and MUO groups. In addition, the level of physical activity in the MHNW group was similar to that in obese groups, possibly because the study was a cross-sectional analysis of a relatively small number of obese subjects. Therefore, it seems premature to purport a conclusion on the effect of the level of physical activity on metabolic health and body weight based on the abovementioned results alone.
However, Hjelmgren et al.9 showed that the MHO group had intermediate levels of beta-cell dysfunction (indirectly measured by plasma proinsulin and C-peptide levels) and insulin resistance assessed by homeostatic model assessment for insulin resistance. Currently, MHO subjects are considered metabolically heterogeneous in terms of risk of type 2 diabetes, although they are classified using different diagnostic criteria.12 Our group demonstrated that elevated high‐sensitivity C‐reactive protein level or increased hepatic steatosis could stratify the risk of type 2 diabetes among MHO subjects.13,14 Although the study by Hjelmgren et al.9 confirmed the intermediate status of MHO subjects in terms of betacell function and insulin resistance, the heterogenous nature of MHO should be considered when assessing the risk of type 2 diabetes in such a population.
The homogenous population of this study is both a strength and a limitation. Another limitation of this study is the cross-sectional study design, whereas metabolic health and obesity status should be considered a dynamic concept.15 Nevertheless, the present study provides valuable information on SRH, level of physical activity, and insulin resistance in MHO individuals. This study also supplements evidence that MHO status is not comparable to MHNW status, as various studies have categorized MHO as an intermediate phenotype between MHNW and MUO phenotypes. The debate on the MHO phenotype and its relationship with possible causes and consequences of obesity persists. Further studies are needed to provide a risk-stratified obesity treatment in MHO patients.
Chang Hee Jung has worked as an Associate Editor of
This work was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (grant No. NRF-2020R1A2C110- 1977 to CHJ). This funding source had no roles in the design of the study; the collection, analysis, and interpretation of data; writing of the article; or the decision to submit the article for publication.
Study concept and design, acquisition of data, and analysis and interpretation of data: all authors; drafting of the manuscript: HSK; critical revision of the manuscript: CHJ; statistical analysis: HSK; obtained funding, administrative, technical, or material support, and study supervision: CHJ.